secwatch.observer — SEC 8-K summary
======================================

Issuer:     Poseida Therapeutics, Inc. (—)
CIK:        0001661460
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001193125-23-085772
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Poseida Therapeutics dismisses PwC, appoints EY as independent auditor for FY2023
--------------------------------------------------------------------------------

- Audit Committee dismissed PwC on March 27, 2023; PwC's 2022 report included an emphasis-of-matter paragraph on additional financing needs.
- No disagreements or reportable events between Poseida and PwC during fiscal years 2022, 2021, and subsequent interim period.
- Ernst & Young LLP appointed as new independent registered public accounting firm for fiscal year ending December 31, 2023.
- Company had not consulted EY on accounting principles or audit opinions prior to engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661460/000119312523085772/0001193125-23-085772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661460/000119312523085772/d471529d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-085772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer